Test Before Treat™ One-pager

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

The PDF document below is a one page summary of what you need to know about the 3 most important tests that need to be done to guide your CLL treatment.

Please feel free to read it, download it, and/or print it out to share with your health care provider, if need be, or with other patients who may benefit from this information.

Test Before Treat™

Once we know that our CLL needs treatment, we need to know how to treat it.

Current NCCN and iwCLL guidelines tell us that it is critical to get appropriate predictive testing before the first and every subsequent therapy. Results of these tests give us information about the biology of our disease, which in turn, gives us the ability to make a reasonable prediction as to which therapies offer us the best chance of success.

Simply put, depending on what the tests show, some commonly prescribed CLL therapies likely will work for us and others may not! 

While there are many tests that might help CLL patients needing treatment to make their most informed decision, these three tests are essential:

  1. FISH (Interphase fluorescence in situ hybridization) test looks for common chromosomal abnormalities that predict the likelihood that various CLL treatments will be effective and durable. For example, if FISH testing finds there is a deletion of the short arm of the 17 chromosome or del(17p) we know that traditional chemo-immunotherapy (CIT) such as fludarabine, cyclophosphamide and rituximab (FCR) or the combination of bendamustine and rituximab known as BR, will not be effective and should be avoided.
  2. Additionally, it is important to test IgVH (also called IgHV, both are correct) mutation status. IgVH mutation status almost never changes over time, so it is generally not recommended that it be retested. It is important because we know that patients with a “mutated” IgVH immunoglobulin do much better with FCR based therapies than those who are unmutated. Generally only patients who have mutated IgVH should consider FCR based therapies.
  3. The 3rd and newest predictive factor is genetic testing for mutation of the TP53 TP53 is the gene on the short arm of the 17th chromosome that helps chemo to work and suppress cancer growth. It has been called the “guardian of the genome” because it tries to repair damaged genetic material in the CLL cells and if can’t repair what’s broken by chemo or any other cause, it signals the cell to commit programmed cell death or apoptosis. You can see how handy TP53 would be in suppressing cancer or helping chemo to work. However, if it’s missing as in del(17p) or mutated, and therefore dysfunctional, as discovered by genetic testing, generally chemotherapy will not work and the CLL can be harder to manage.

If you know the status of these 3 tests before your 1st and every subsequent treatment you can best map out your treatment strategy. FISH and TP53 need to be checked and rechecked before the first and any subsequent treatments as they can change over time, usually for the worse. IgVH mutation status is considered stable over time.

Test Before Treat™

  • Test FISH and TP53 Mutation before every treatment
  • Test IgVH mutation status before the 1st treatment
  • Deletion 17p or del(17p) = NO CHEMOTHERAPY
  • TP53 mutation = NO CHEMOTHERAPY
  • IgVH unmutated = NO FCR
  • IgVH mutated = possible FCR


(Expert Access & Test Before Treat™) This is just a brief note to tell you about the important impact you had on my treatment for CLL. Last November, through the Expert Access program sponsored by the CLL Society, you were kind enough to review my medical records and chat
When I was first diagnosed in April 2018, my WBC was at 55k, my local Hematologist performed the FISH test and found out I had 11Q with loss of ATM, they told me that only made a difference in the type of treatment I would need and I probably
Diagnosed Aug 2018 as a 54-year-old female, with SLL via node biopsy. CT showed extensive lymphadenopathy, very bulky disease, particularly in mesentery. Bloodwork all in normal range. Had BMB in spring 2019 for purposes of FISH. Had been experiencing increasing fatigue and discomfort in gut. Pathologist decided not to
I question if my doctor should have genetic tested me before treating me with Bendamustine in December 2013 and if this was the cause of my developing theTP53 mutation after my initial diagnosis of 13q in 2008. After the Bendamustine treatments, I started on Ibrutinib in January 2014. Gary
I was diagnosed accidentally in 2001 during investigation of a single swollen cervical node. My community oncologist at Maine Medical Center recommended chemo immediately. A comprehensive second opinion from Dana Farber led to 15 years of asymptomatic watch and wait. In 2015 a dramatic appearance of symptoms over 3
August 2019 I was diagnosed with CLL in June of 2014. Like most CLL patients, I was originally placed on watch and wait, but my cancer progressed aggressively. After only 17 months, my WBC had exploded higher (it peaked at 350,000 cells per cubic millimeter of blood, up from
At the time of my initial diagnosis — and not because I knew any better, because I knew nothing at all including my not-yet-announced diagnosis – my hematologist ran both a flow cytometry (to diagnose my disease) and a FISH analysis (to explore the genetics of my CLL). Though